Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.63 |
| ▸ | XDH | P47989 | 3/20 | 0.58 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | POLA1 | P09884 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2051369 | 0.83 | GDA (0.63) | GDAXDHPNPPOLA1 | |
| SCHEMBL29407603 | 0.83 | GDA (0.63) | GDAXDHPNPPOLA1 | |
| SCHEMBL20580 | 0.83 | GDA (0.63) | GDAXDHPNPPOLA1 | |
| SCHEMBL22885 | 0.83 | GDA (0.68) | GDAXDHPNPPOLA1 | |
| SCHEMBL2983854 | 0.83 | GDA (0.68) | GDAXDHPNPPOLA1 | |
| SCHEMBL8886042 | 0.83 | GDA (0.63) | GDAXDHPNPPOLA1 | |
| SCHEMBL41789 | 0.83 | GDA (0.63) | GDAXDHPNPPOLA1 | |
| SCHEMBL1843779 | 0.83 | GDA (0.63) | GDAXDHPNPPOLA1 | |
| SCHEMBL29174357 | 0.82 | GDA (0.58) | GDAXDHPNPPOLA1 | |
| SCHEMBL9960821 | 0.81 | XDH (0.69) | GDAXDHPNPPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644384-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR | BRISTOL MYERS SQUIBB CO (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2433941-A1 | Process for isolating the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | Bristol-Myers Squibb Company (US) | 2012-03-28 | — | — | EP | disclosed |
| CN-101130543-B | Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one | BRISTOL MYERS SQUIBB CO | 2011-06-08 | — | — | CN | disclosed |
| CN-101130552-B | Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one | BRISTOL MYERS SQUIBB CO | 2010-07-28 | — | — | CN | disclosed |
| US-7550619-B2 | Intermediates in the preparation of the antiviral agent [1S-(1α, 3α, 4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxmethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7541460-B2 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-3-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| CN-100379746-C | Process for the preparation of the antiviral agent [ 1S- (1 α,3 α,4 β) ] -2-amino-1, 9-dihydro-9- [ 4-hydroxy-3- (hydroxymethyl) -2-methylenecyclopentyl ] -6H-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2008-04-09 | — | — | CN | disclosed |
| CN-101130543-A | Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2008-02-27 | — | — | CN | disclosed |
| CN-101130552-A | Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2008-02-27 | — | — | CN | disclosed |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | CHAN YEUNG Y | 2006-05-18 | — | — | US | disclosed |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | PENDRI YADAGIRI R | 2006-05-18 | — | — | US | disclosed |
| US-7034152-B2 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1644384-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1414822-B1 | IMPROVED SYNTHESIS OF BRANCHED ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-30 | — | — | US | disclosed |
| US-20040147743-A1 | Synthesis of branched acyclic nucleosides | BANK OF NEW YORK, THE | 2004-07-29 | — | — | US | disclosed |
| WO-2004052310-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| EP-1414822-A1 | IMPROVED SYNTHESIS OF BRANCHED ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003002564-A1 | IMPROVED SYNTHESIS OF BRANCHED ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 2003-01-09 | — | — | WO | disclosed |
| WO-1999030561-A1 | NUCLEOTIDE-BASED PRODRUGS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | GDA 683/4885XDH 1461/4885PNP 19/4885 |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | GDA 686/4885XDH 1527/4885PNP 21/4885 |
| US-20040147743-A1 | Synthesis of branched acyclic nucleosides | SI, POLL, ME1 | GDA 153/4885XDH 287/4885PNP 17/4885 |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | GDA 686/4885XDH 1527/4885PNP 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.